Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-Dose Daunorubicin in Relapsed/Refractory Acute Leukemia
NCT02914977Phase 1Completed
- Start
- Nov 2016
- Primary completion
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of daunorubicin in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). Primary endpoint: Molecular pharmacodynamic effect of low dose daunorubicin on beta-catenin phosphorylation at 12 months. Started Nov 2016; status: completed.
02
Drugs
daunorubicin
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT02914977.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02914977.